Emory University

Cancer Research Technology Limited

Imperial Innovations Limited

Children's Healthcare of Atlanta, Inc.

Imperial College of Science, Technology and Medicine

Ip2ipo Innovations Limited

Neurop, Inc.

Imperial College Innovations Limited

Searle & Co.

Fowler, Kerry W.

Chorvat, Robert J.

Snyder, James P.

James P Snyder

Dennis C Liotta

Hariharan Venkatesan

Matthew John Fuchter

Aiming Sun

Simak Ali

Richard K Plemper

Alexander Bondke

Charles Coombes

Anthony Barrett

Sebastian Kroll

Brian Slafer

Stephen F Traynelis

Lawrence J Wilson

Raymond J Dingledine

Susheng Wang

Weiqiang Zhan

Matthew C Davis

Brian Adams

Mamoru Shoji

Eva M Ferstl

Ustun B Sunay

Michael V Voronkov

Laura Captain

Marcus A Schestopol

Anthony G M Barrett

Hyunsuk Shim

Yesim Altas Tahirovic

Scott James Myers

Ashutosh S Jogalekar

Zhongxing Liang

Cara Mosley

Michael G Natchus

Robert J Chorvat

Kerry W Fowler

Robert Albert Brown

Thota Ganesh

Bodo Scheiper

Bryan D Cox

Jin Liu

Zackery Will Dentmon

Qi Shi

Matthew J Cook

Thomas Kaiser

Sebastian H B Kroll

Anthony Prosser

John DiRaddo

Raoul Charles Dalmedo Stuart Coombes

Aleksandra Siwicka

Nadine Chapman-Rothe

Jan Brackow

Nitipol Srimongkolpithak

Joachim Caron

Yesim Altas

David D Mott

James J Doherty, Jr

John M Ndungu

Jeong-Joong Yoon

Serdar Kurtkaya

Iestyn Lewis

Scott Myers

Lawrence Wilson

Robert Brown

Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.

Phosphotidylinositol 3-kinase inhibitors

The disclosure relates to chemokine receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing chemokine related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.

Chemokine CXCR4 and CCR5 receptor modulators and uses related thereto

Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use

This invention relates to quinazoline compounds of Formula (I) which are inhibitors of the histone lysine methyltransferase (HKMTase) EZH2, and to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of EZH2 provides a therapeutic or prophylactic effect. 

Quinazoline compounds and their use in therapy

This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: or salt, prodrug, or ester thereof wherein X, Y, and Rand Rto Rare described herein.

Myxovirus therapeutics, compounds, and uses related thereto

This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and Rand Rto Rare described herein. 

This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising 2-((benzo[d]imidazol-2-yl)thio)-N-phenylpropanamide derivatives, N-phenyl-2-((1-phenyl-benzo[d]imidazol-2-yl)thio)propanamide derivatives, or 2-((benzo[d]imidazol-2-yl)thio)-N-(2-chloro-4-methylphenyl)propanamide derivatives. The derivatives may be substituted with one or more substituents. Typically, the pharmaceutical composition comprises a compound of Formula (I), or salt, prodrug, or ester thereof wherein X, Y, and R1 to R7 are described herein. 

Imidazolyl amide compounds and uses related thereto

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein:

NMDA receptor antagonists for neuroprotection

Embodiments of the present disclosure include methods for identifying a compound or compounds useful as therapeutic agents in the treatment of paramyxovirus infections, compounds for the treatment of measles, and high throughput screening methods for identifying compounds capable of inhibiting the proliferation of a paramyxovirus.

Paramyxovirus family inhibitors and methods of use thereof

Processes for the preparation of certain 5,7-diaminopyrazolo[1,5-&#x3b1;]pyrimidine compounds comprising the reaction of a primary or secondary amine and a protected 5-halo-7-aminopyrazolo[1,5-&#x3b1;]pyrimidine compound in solvent system comprising water and one or more organic solvents, optionally in the presence of an exogenous base.

Process for preparing 5,7 diaminopyrazolo [1,5-A] pyrimidine compounds

Graphical user interface for a display screen or a portion thereof

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: wherein:each (L)-Aris a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NRor O and each Rand Ris independently H, alkyl, alkenyl or aralkyl or Rand Rtaken together form a 5-8 membered ring; RRare selected from certain specific substituents or a carbonyl; Y is a bond, O, S, SO, SO, CH, NH, N(alkyl), or NHC(&#x2550;O); and Z is OH, NRR, NRSO(alkyl), NRC(O)NRR, NRC(O)O(alkyl), NR-dihydrothiazole, or NR-dihydroimidazole or wherein Z can fuse with Arto form selected heterocycles.

Growing community of inventors

Atlanta, GA, United States of America

James P Snyder